Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Stock Information for KALA BIO Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About KALA BIO Inc.

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.